Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03242954 · ClinicalTrials.gov registry record · NA

Innovative Approaches for Minor Consent: Consent 2.0

A NA study of HIV, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
254
Enrollment target
4
Study locations

NCT03242954 is a NA study of HIV that has completed, run by Indiana University. The registered enrollment target is 254 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (42% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03242954, a NA study of HIV, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
254 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to examine how the consent process affects the acceptability of participation in biomedical HIV prevention trials, from the perspective of behaviorally high-risk minors and the parents of minor adolescents.

Conditions Studied

Interventions

  • OTHER Autonomous minor consent
  • OTHER Adult permission required
  • OTHER Parental permission required

Study Locations (4)

Colorado

  • Children's Hospital Colorado/Univ of Colorado SOM - Aurora

Florida

  • University of South Florida - Tampa

Illinois

  • University of Chicago - Chicago

Maryland

  • Johns Hopkins University/SOM - Baltimore

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2017-11-07
Est. Completion 2019-09-15
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT03242954

The ClinicalTrials.gov registry entry for NCT03242954 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (42% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 3 interventions - of which Autonomous minor consent is the first listed.

NCT03242954 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT03242954 about?

NCT03242954 is a clinical study titled "Innovative Approaches for Minor Consent: Consent 2.0". The purpose of this study is to examine how the consent process affects the acceptability of participation in biomedical HIV prevention trials, from the perspective of behaviorally high-risk minors and the parents of minor adolescents.

What is the current status of trial NCT03242954?

This trial is currently completed. It is a NA study. The enrollment target is 254 participants. The study started on 2017-11-07. Estimated completion is 2019-09-15.

What conditions does trial NCT03242954 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT03242954?

The interventions under investigation include: Autonomous minor consent (OTHER), Adult permission required (OTHER), Parental permission required (OTHER).

Who is sponsoring clinical trial NCT03242954?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03242954 being conducted?

This trial has 4 study locations across Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.